Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2008 September;20(3) > Minerva Biotecnologica 2008 September;20(3):133-5

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

TECHNICAL NOTES   

Minerva Biotecnologica 2008 September;20(3):133-5

Copyright © 2008 EDIZIONI MINERVA MEDICA

language: English

A simultaneous dual-isotope acquisition and imaging fusion protocol in nuclear medicine: 111In-Octreotide SPECT and 99mTc-HMDP bone SPECT

Zanotti-Fregonara P. 1, Keller I. 2, Devaux J. Y. 2, Massaro A. 3, Rubello D. 3, Hindié E. 4

1 DSV/IBM/SHFJ/LIME Commissariat à l’Energie Atomique, Orsay, France 2 Service de Médecine Nucléaire Hôpital St Antoine, Paris, France 3 Department of Nuclear Medicine PET Center, S. Maria della Misericordia Hospital, Rovigo, Italy 4 Service de Médecine Nucléaire, Hôpital St Louis, Paris, France


PDF


In the present preliminary study, we developed a protocol for the acquisition and fusion of dual-isotope tomographic (SPECT) images (111In-Octreotide SPECT and 99mTc-HMDP SPECT). This procedure was performed in ten consecutive patients, and the first results were encouraging: it proved to be a simple and accurate method to improve the anatomic localization of 111In-Octreotide SPECT positive foci for the staging and follow-up of tumours expressing somatostatin receptors (Octreotide is an analog of somatostatin), particularly in discriminating bone metastases from soft tissue metastases located near to bone itself.

top of page